AU2013286812B2 - Treatment of inflammatory skin disorders - Google Patents

Treatment of inflammatory skin disorders Download PDF

Info

Publication number
AU2013286812B2
AU2013286812B2 AU2013286812A AU2013286812A AU2013286812B2 AU 2013286812 B2 AU2013286812 B2 AU 2013286812B2 AU 2013286812 A AU2013286812 A AU 2013286812A AU 2013286812 A AU2013286812 A AU 2013286812A AU 2013286812 B2 AU2013286812 B2 AU 2013286812B2
Authority
AU
Australia
Prior art keywords
apc
skin
individual
psoriasis
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013286812A
Other languages
English (en)
Other versions
AU2013286812A1 (en
Inventor
Christopher John Jackson
Meilang Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
ZZ Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by ZZ Biotech LLC filed Critical ZZ Biotech LLC
Priority to AU2013286812A priority Critical patent/AU2013286812B2/en
Publication of AU2013286812A1 publication Critical patent/AU2013286812A1/en
Assigned to ZZ BIOTECH LLC reassignment ZZ BIOTECH LLC Request for Assignment Assignors: THE UNIVERSITY OF SYDNEY
Application granted granted Critical
Publication of AU2013286812B2 publication Critical patent/AU2013286812B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013286812A 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders Active AU2013286812B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013286812A AU2013286812B2 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
AU2012902874 2012-07-04
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders
AU2013286812A AU2013286812B2 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (2)

Publication Number Publication Date
AU2013286812A1 AU2013286812A1 (en) 2015-01-22
AU2013286812B2 true AU2013286812B2 (en) 2017-04-20

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013286812A Active AU2013286812B2 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Country Status (12)

Country Link
US (3) US20150150954A1 (enExample)
EP (1) EP2869833B1 (enExample)
JP (1) JP6273272B2 (enExample)
KR (1) KR102068010B1 (enExample)
CN (1) CN104394883B (enExample)
AU (1) AU2013286812B2 (enExample)
BR (1) BR112015000051A2 (enExample)
CA (1) CA2877745C (enExample)
ES (1) ES2676422T3 (enExample)
IN (1) IN2014DN11181A (enExample)
RU (1) RU2662564C2 (enExample)
WO (1) WO2014005183A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005183A1 (en) * 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
PT3131572T (pt) * 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas
PL3137102T3 (pl) * 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
KR20210121039A (ko) * 2018-12-26 2021-10-07 다이렉트 바이오로직스 엘엘씨 피부 및 모발 장애를 치료하기 위한 방법 및 조성물
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
AU2467395A (en) 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
CZ298429B6 (cs) 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
KR20030060915A (ko) 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
EP1404412B1 (en) * 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
DK1477166T3 (da) 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
ZA200800255B (en) 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
ES2431050T3 (es) * 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
US20100284997A1 (en) 2006-10-31 2010-11-11 Griffin John H Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
MX2011010401A (es) * 2009-04-01 2012-01-20 Rappaport Family Inst Res In The Medical Sciences Un metodo para regular la proliferacion y deferenciacion de queratinocitos.
WO2014005183A1 (en) * 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法

Also Published As

Publication number Publication date
CN104394883B (zh) 2017-05-31
HK1204573A1 (en) 2015-11-27
US20200276281A1 (en) 2020-09-03
EP2869833B1 (en) 2018-04-04
BR112015000051A2 (pt) 2017-06-27
CA2877745A1 (en) 2014-01-09
CA2877745C (en) 2021-11-30
IN2014DN11181A (enExample) 2015-10-02
RU2015103510A (ru) 2016-08-27
US20170080062A1 (en) 2017-03-23
EP2869833A1 (en) 2015-05-13
CN104394883A (zh) 2015-03-04
US11617785B2 (en) 2023-04-04
KR20150036351A (ko) 2015-04-07
WO2014005183A1 (en) 2014-01-09
KR102068010B1 (ko) 2020-01-20
AU2013286812A1 (en) 2015-01-22
JP6273272B2 (ja) 2018-01-31
ES2676422T3 (es) 2018-07-19
US20150150954A1 (en) 2015-06-04
JP2015521632A (ja) 2015-07-30
EP2869833A4 (en) 2015-11-18
RU2662564C2 (ru) 2018-07-26

Similar Documents

Publication Publication Date Title
US11617785B2 (en) Treatment of inflammatory skin disorders
Anzengruber et al. Swiss S1 guideline for the treatment of rosacea
Roda et al. Infliximab therapy for Netherton syndrome: a case report
Oyamada et al. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion
TWI868051B (zh) 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
US11491214B2 (en) Treatment of abnormal cutaneous scarring
Veeravalli Implications of MMP-12 in the pathophysiology of ischaemic stroke
Sotiriou et al. Etanercept for the treatment of hidradenitis suppurativa
HK1204573B (en) Treatment of inflammatory skin disorders
Cole Dermatologic Therapies
Bubna et al. Brodalumab: Looking beyond psoriasis
Bubna IL-17 Antagonists
HK1235306B (zh) 治疗异常皮肤瘢痕形成
ZHENG Overview of the drug therapy for Psoriasis
Kivelevitch et al. Palmoplantar psoriasis
Kansara et al. CONVENTIONAL TOPICAL TREATMENTS OF PSORIASIS
Rabasseda A report from the 72nd Annual Meeting of the American Academy of Dermatology (March 21-25, Denver, Colorado, USA)
Ogunbanjo et al. A family practice snapshot

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ZZ BIOTECH LLC

Free format text: FORMER APPLICANT(S): THE UNIVERSITY OF SYDNEY

FGA Letters patent sealed or granted (standard patent)